7 results about "Vaccine Stability" patented technology

The application discloses circular RNA and application thereof in pigeon trichomonad vaccine. The circular RNA comprises a coding element capable of encoding recombinant pigeon trichomonad AP33 or AP65 protein. The coding element has a sequence shown in SEQ ID NO. 1 or SEQ ID NO. 2 or a conservatively variant sequence thereof. The circular RNA can induce protein expression and generate high-level antibodies in an animal body. When the circular RNA is applied to the pigeon trichomonad vaccine, the circular RNA does not contain infectious worm component, can be degraded into nucleotides in the body, cannot be integrated into a host genome, has no risk for pigeons, can stimulate pigeons to generate a stronger immune response, including humoral immunity and cellular immunity, and can effectively resist parasitic infection. Meanwhile, the vaccine has high stability, the vaccine of the application can be prepared on a large scale through a molecular technology, and production cost is low.

The invention relates to the technical field of mRNA vaccine preparation, and particularly discloses a porcine epidemic diarrhea virus mRNA vaccine and a preparation method thereof. The mRNA vaccine is prepared by adopting cow milk source exosome as a carrier and wrapping mRNA encoding PEDV-S protein in the carrier through an ultrasonic loading method. According to the preparation method, the encapsulation efficiency of mRNA and the stability of the vaccine are remarkably improved, the prepared vaccine can more efficiently promote antigen expression, stronger cellular immunity and humoral immunity are induced in a mouse body, and a safe and efficient novel vaccine candidate is provided for preventing and controlling porcine epidemic diarrhea.

The application discloses an oral drug delivery system targeting mesenteric lymph nodes, prepares a novel LNP oral delivery carrier simulating drug release of chylomicron, and explores a pathway and method of intestinal chylomicron lymphatic vessel targeting by modifying a carrier material with a targeting group. Compared with the prior art, the application can significantly improve the ability of nano-drugs to penetrate the intestinal epithelial barrier, enhance the targeting of nano-drugs, and has significant advantages in improving vaccine stability, enhancing immune response and reducing side effects through calcium alginate hydrogel wrapping.

The invention discloses a circular RNA vaccine based on a vasoactive intestinal peptide delivery system and application of the circular RNA vaccine, and relates to the field of RNA vaccines. Comprising vasoactive intestinal peptide VIP serving as a delivery carrier and circular RNA for coding a respiratory syncytial virus RSVpreF antigen, and the vasoactive intestinal peptide VIP and the circular RNA form a compound through non-covalent linkage; the vasoactive intestinal peptide VIP is a VIP-EGFP-N fusion protein. According to the invention, the function of the VIP as a high-efficiency cell-penetrating peptide is explored and verified for the first time, and the VIP is combined with a circular RNA molecule of a coding RSV key antigen protein preF to construct a safe, stable and high-efficiency RSV vaccine, so that the technical bottlenecks of poor stability of the existing mRNA vaccine, complex and low-efficiency LNP delivery system, insufficient immunogenicity or poor safety of the traditional RSV vaccine and the like are solved.

The utility model discloses a kind of emulsification devices for vaccine production, it is related to vaccine emulsification technical field, including cooling cavity, the emulsification cup is arranged in the inside of cooling cavity, the base is arranged in the lower end of cooling cavity, the fixed frame is arranged in the upper end of base, the cooling pipe is arranged in the right side of cooling cavity, the water storage chamber is arranged in the lower end of cooling pipe, the outer wall of cooling pipe is provided with multiple groups of fixers, the water inlet is arranged in the upper end of water storage chamber, the water pump is arranged in one side of water storage chamber, the transmission rod is arranged in the inside of emulsification cup, the outer wall of transmission rod is provided with auger shaft, the first motor is arranged in the lower end of transmission rod.The utility model of a kind of emulsification devices for vaccine production, cooling liquid can be circulated in cooling pipe, to cool emulsification cup, can avoid that environment temperature or vaccine emulsification temperature is too high, can keep vaccine stability, reduce foam generation and optimize emulsification effect.

The invention relates to the technical field of veterinary biological products, and discloses a porcine pseudorabies virus gene deletion inactivated vaccine preparation process, which comprises: S1, carrying out serum-free suspension culture on a porcine pseudorabies virus; s2, virus content detection; s3, an antigen treatment and purification process; and S4, proportioning and emulsifying the inactivated vaccine. The prepared suspension virus is high in content, short in culture period, simple and stable in purification process and easy to operate, the production cost can be greatly reduced, meanwhile, vaccine preparation proportion of antigens is optimized, the purification loss rate is low, antigen purity is high, immunogenicity is enhanced, side reactions of pigs can be reduced, vaccine batch difference is reduced, the quality is easy to control, and the method is suitable for large-scale popularization and application. The vaccine yield and quality can be remarkably improved, the vaccine protection rate is increased, the vaccine stability duration is long, the immune effect is enhanced, the inter-batch difference is reduced, and the immune duration is enhanced.

The invention discloses a circular RNA (Ribonucleic Acid) and an application of the circular RNA in a trichomonad pigeon vaccine. The coding element contained in the circular RNA can be used for coding the recombinant trichomonas pigeon AP33 or AP65 protein. The coding element has a sequence as shown in SEQ ID NO.1 or SEQ ID NO.2 or a conservative variant sequence of the sequence as shown in SEQ ID NO.1 or SEQ ID NO.2. The circular RNA can induce protein expression in an animal body and generate a high-level antibody, does not contain infectious insect species components, can be degraded into nucleotides in the body and cannot be integrated into a host genome when being applied to a trichomonad pigeon vaccine, has no risk to pigeons in use, can stimulate the pigeons to generate relatively strong immune responses including humoral immunity and cellular immunity, and can be used for preparing a vaccine for preventing and treating the pigeons. Meanwhile, the vaccine is high in stability, can be prepared on a large scale through a molecular technology, and is low in production cost.